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A B S T R A C T
Bosnia and Herzegovina (B&H) is one of the Eastern European countries with lacking data on thyroid cancer (TC)
epidemiology. We aimed to assess the incidence of TC in Tuzla Canton of B&H during a 10-year period (1999–2008). We
retrospectively evaluated 65000 hospital records of both inpatients and outpatients with possible thyroid symptoms resid-
ing in Tuzla Canton of B&H (total of 496280 inhabitants) between 1999 and 2008. Patients with histological proof of TC
were included in study. Incidence rates were calculated with age standardisation using European standard population.
Trends in incidence were evaluated as moving three-year averages. During observed period 117 patients met the diag-
nostic criteria for TC with male to female ratio of 1:4.85. Median age of all cases was 51 years (interquartile range: 41 to
60) with men in average 9 years older than women at the time of diagnosis. The mean annual standardized incidence
was found to be 2.30/105 (%95 CI=1.38–3.22) inhabitants ranging from 1.0 to 3.2 per 105. The average crude incidence in
men was 0.82/105 and 3.83/105 in women. The prevalence of TC, at the end of the observed period was found to be
23.58/105 (%95 CI=19.3–27.58). There is a slight decline of incidence in our region during the observed period, but with
the increase in the latest years of the study. This increase is probably the result of combination of various factors, mainly
the better detection of new cases due to wider availability of diagnostics. Based on depicted trends, we believe that in the
future years, TC incidence in our region will continue to rise.
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Introduction
It is estimated that thyroid cancer (TC) accounts for
around 0.5 to 1 percent of all malignancies in human
pathology1. Thyroid cancer is therefore, not as frequent
when compared to more common benign thyroid dis-
eases. Still, more than 1200 people die every year in USA
as a consequence of this disease.
Although epidemiology of TC throughout the World
and Western Europe is well described1–9, data on epide-
miology of TC in the region of southeast Europe is sparse
and almost non-existent. There are several incomplete
reports from Croatia and Serbia10,11, while Bosnia and
Herzegovina remains a region without reported data on
epidemiology of TC. The only data available is the GLO-
BOCAN 2002 estimate – calculated by using the average
rates in neighbouring countries12.
Therefore, we aimed through 10-year retrospective
review of our hospital records to assess epidemiological
data on TC in a geographically well-defined region of
Tuzla in northeast of Bosnia and Herzegovina.
Subjects and Methods
Settings
Bosnia and Herzegovina (B&H), since the end of
Bosnian War (1992–1995) has two entities – Federation
of Bosnia and Herzegovina and Republic of Srpska. Fed-
eration of Bosnia and Herzegovina further consists of 10
cantons, among which is the Tuzla Canton – well defined
region in northeast of Bosnia and Herzegovina (Figure
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1). Estimated population in the region on December 31st,
2006 is 496280 (Federal Office of Statistics, Federation of
Bosnia and Herzegovina, Sarajevo). Population in the re-
gion have been relatively stable since the war, yet the lat-
est national census has not been performed since 1991,
so most of the population data is based on estimates.
University Clinical Centre Tuzla is a regional hospital
centre and serves as a secondary and tertiary referral
centre for the region. All patients with TC, residing in
the region are therefore, mostly diagnosed in our centre.
Medications used for treating TC are on Tuzla Canton
Formulary List and are either free of charge or at a re-
duced price rate. But they can be prescribed only after
written recommendation given by physicians in our hos-
pital. Hence, one can assume that, in order for a patient
with TC to receive medications, he has to be evaluated by
a specialist in our hospital, which allows us to register
and follow up most (if not all) of the patients residing in
our region.
Patients and Methods
We retrospectively analyzed 65000 hospital records of
both inpatients and outpatients with possible thyroid
disease residing in Tuzla Canton of B&H between 1.1.
1999 and 31.12.2008. We excluded all patients that did
not reside in Tuzla Canton. After that, we selected all pa-
tients with histological confirmation of thyroid cancer.
We also recorded age, gender, date of initial diagnosis,
size of primary tumour (cm), presence of extra thyroid
invasion, presence of metastases, pTNM stage and clini-
cal stage. Our records did not always contain sufficient
clinical data to separate medullary carcinoma within
multiple endocrine neoplasia (MEN) and without MEN,
therefore both types were included in survival.
We classified tumours into 4 main histological types
(papillary, follicular, medullar and anaplastic) according
to WHO classification and using methodology previously
described7. Patients with other types of tumours of thy-
roid gland such as other types of carcinomas, lympho-
mas, mesenchimal tumours and metastatic tumours
were excluded from further analysis, mainly due to a
very small (or non-existent) number of cases.
Statistical analysis
Statistical analysis was performed using SPSS 15.0
(SPSS, Chicago, IL, USA). Descriptive statistics has been
used for determination of baseline characteristics. The
year of diagnosis was used to date incidence. Calculations
of TC incidence have been performed based on the latest
(December 31st, 2008) population estimates in our region
obtained from the Federal Office of Statistics, Federation
of Bosnia and Herzegovina, Sarajevo. Ninety five per
cent confidence intervals (95% CI) of incidence rates
were estimated assuming a Poisson distribution of cases.
Crude annual incidence rates were calculated based on
the number of patients diagnosed and the number of in-
habitants for both sexes while average incidence rate
during observed period was calculated based on number
of study years. Age standardized incidence rates were
calculated using European standard population weights
(22, 14, 14, 14, 14, 11, 7, 4) for each of our age group13.
Trends in incidence from 1995–2006 were evaluated as
moving three-year averages with %95 CI. Trends in inci-
dence were also evaluated using linear regression model
where applicable. Prevalence estimate during observed
period was estimated based on the total number of cases
detected and the number of inhabitants according to lat-
est population estimates. Statistical level of 95% (p<
0.05) was considered as significant for all performed
tests.
Results
During the 10-year period we registered 117 cases of
TC with 97/117 (82.9%) of female and 20/117 (17.1%) of
male patients – male to female ratio 1 to 4.85.
The median age in all patients with TC was 51 year
(interquartile range 41 to 60 years) with a range span-
ning from 11 to 77 years. Female patients (48.7±13.3
years) were in average 9 years (%95 CI=2.4–15.5; p=
0.008) younger than male patients (57.7±14.3 years).
The largest proportion of patients in our sample (77/
117; 66%) had papillary type of carcinoma, 33 patients
(28%) had follicular type, 5 patients (4%) had medullar
type while remaining 2 (2%) had anaplastic type of thy-
roid carcinoma.
The TNM stage of patients at the time of diagnosis is
presented at the table 1. Most of the patients (46/117;
39%) were at the clinical stage III, followed by 39 (33%)
patients at stage I, 17 (15%) at stage IV and 15 (13%) at
stage I.
The average annual crude incidence of thyroid cancer
during the observed period was 2.36/105 population (%95
CI=1.93–2.78). The average crude incidence in men was
0.82/105 and 3.83/105 in women.
After we performed standardization according to
standard European population, the average annual stan-
dardized incidence during the time period 1999–2008
was 2.30/105 (%95 CI=1.38–3.22).
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Fig. 1. Map of Bosnia and Herzegovina, showing the Tuzla
Canton (solid black area).
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The sum prevalence during the study period calcu-
lated for population numbers on 31.12.2008, was 23.58/
105 population (%95CI=19.30–27.85). Prevalence among
men was 8.24/105 (%95 CI=4.63–11.85) and 38.27/105
(%95 CI=30.66–45.89) among women.
The annual incidence for men and women and com-
plete sample is depicted in Figure 2. As demonstrated in-
cidence rates for the complete sample spanned between
1/105 and 3.2/105. The largest incidence recorded was
among women in year 2000 (5.92/105).
A trend in incidence during the observed period is de-
picted in figure 3 as moving three-year average with 95%
confidence intervals. The slight decline in incidence dur-
ing the observed period is indeed noticeable which was
confirmed with linear regression line which is also pre-
sented in the same figure.
The graphic display of incidence according to gender
and age is presented in figure 4. The largest incidence
was found in women age 55–64, while peak incidence in
men was in older age group of 65–74.
Out of 117 cases of TC we recorded total of 5 patients
with lethal outcome (4,3%). Anaplastic TC was cause of
death in 2/5 (40%) of patients, while follicular cancer was
cause of death in the remaining 3 (60%) patients. The
mean time to death was 28 months (%95CI=6–50months),
with significant difference (X2=4,26; df=1; p=0,04) be-
tween anaplastic cancer (mean time to death 2 months;
%95 CI=0–4 months) and folicular cancer (mean time to
death 45 months; %95 CI=33–57 months).
Discussion
As already stated, the only data on epidemiology of
TC in the Bosnia and Herzegovina is available through
GLOBOCAN 2002 project that is based on the estimate –
the crude average of the numbers in the neighbouring
countries. According to GLOBOCAN it was estimated
A. Salki} et al.: Thyroid Cancer in Tuzla Canton, Bosnia and Herzegovina, 1998–2009, Coll. Antropol. 36 (2012) Suppl. 2: 53–57
55
TABLE 1
PROPORTION OF STAGES OF THYROID CANCER ACCORDING TO PTNM CLASSIFICATION
pTNM classification
T N M
1 2 3 4 0 1 0 1
Age
£45 years
N 13 7 16 7 31 12 40 3
% 43.3% 35.0% 37.2% 29.2% 36.9% 36.4% 37.4% 30.0%
>45 years
N 17 13 27 17 53 21 67 7
% 56.7% 65.0% 62.8% 70.8% 63.1% 63.6% 62.6% 70.0%
Total 30 20 43 24 84 33 107 10
Fig. 2. Annual incidence of thyroid cancer in Tuzla region of
Bosnia and Herzegovina during the period 1999–2008 in both
gender and complete sample.
Fig. 3. Trend of annual incidence of thyroid cancer in Tuzla
region of Bosnia and Herzegovina during the period 1999–
2008. Dotted line represents the linear regression trendline;
vertical lines represent confidence intervals.
Fig. 4. Incidence of thyroid cancer according to age at the time of
diagnosis and gender of the patient.
U:\coll-antropolo\coll-antro-(Suppl 2)-2012\29 Salkic.vp
20. studeni 2012 13:34:40
Color profile: Generic CMYK printer profile
Composite  150 lpi at 45 degrees
that the average crude incidence of TC among men
equals to 1.8/105 and 5.2/105 among women.12 Our re-
sults indicate that numbers regarding the incidence in
the Tuzla region of B&H may be a little smaller with
0.82/105 among men and 3.83/105 among women.
Compared to published data on incidence in the
neighbouring countries it appears that Croatia has sig-
nificantly higher incidence (8.8 and 2.5 per 105 for wo-
men and men, respectively) again, according to GLOBO-
CAN report. At the other end of the spectre is another
neighbouring country – Serbia and Montenegro (num-
bers reported before those two countries separated) with
incidence rates of 2.1/105 among women and 0.9/105
among men. Apparently our figures reside in the middle.
However it is important to discuss the reasons for such
differences in a relatively small region.
The most probable explanation for lower incidence is
that is the result of a poor ascertainment and lack of reli-
able diagnostics. It is not a secret that B&H is a develop-
ing country struggling to cope with the consequences of
the terrible war. The availability of both the equipment
and trained physicians may be an important contribut-
ing factor to false reduction of incidence rates. This is
reason why we encounter more patients with advanced
TC at diagnosis (Table 1); they are probably detected
later during the natural course of their disease.
Another possible explanation may be the Chernobyl
accident; according to United Nations Scientific Commit-
tee on the Effects of Atomic Radiation, Croatia was one
of the countries with the highest exposition to nuclear
contamination after the accident14. It has been widely
speculated that beside improved diagnostics, Chernobyl
incident may be another contributing factor in the rise of
incidence of thyroid cancer witnessed throughout the
Europe in the last 20 years3–5,9,10. Tuzla region lies be-
hind the rather high mountainous region in the north,
which might have provided some protection against wind
carried radioactive clouds during the incident.
Of course there is an issue of high variability of TC in-
cidence in different countries that also needs to be men-
tioned. Recently published study analyzed trends in inci-
dence of TC in various countries on several continents3.
With exception of Sweden, all of the analyzed countries
reported rise in incidence rates. However, there were sig-
nificant variations in incidence rates among countries
belonging to the same continents, with the exception of
Africa with a very low incidence reported in all of coun-
tries.
Incidence of TC is on the continuing rise in the last
10–20 years; several studies from various regions of the
World irrefutably confirm this fact4,6,9,15–19. Although this
trend in rise of the incidence is a consequence of the ex-
posure to various risk factors such as radiation, iodine
supplementation etc, an important additional factor that
at least partially results in the rise of incidence is in-
crease in the number of diagnostic procedures, availabil-
ity of sophisticated diagnostic methods and change in
histological criteria20.
There is also an interesting phenomenon observed
during the study period. During the 3-year time period of
2003–2005 there is apparent nadir of incidence with a
subsequent rise in the later study years. The correspond-
ing line consequently has the shape of the wide letter V
(Figure 3). This also does not correspond with the real
decline in incidence but rather with the lower availability
of diagnostic procedures in our hospital in that particular
time period. This is purely a result of frequent equip-
ment malfunctions, lack of educated physicians that we
encountered. Rise of incidence in the following years,
once we successfully remedied all of the listed problems
is another indirect proof of our claim.
The higher ratio of female patients with TC (4.85 to 1)
in our study is not surprising. Domination of female pa-
tients is a well established fact reported in numerous
studies3–8,20,21. Also, according to our results men were in
average 9 years older at the moment of the diagnosis.
This was also recognized in several previously published
studies2,4,6. This is why female gender is a firmly estab-
lished risk factor for all types of thyroid cancer22.
There are several limitations of this study that need
to be mentioned. This is a hospital-based series and there
is a possible limitation of referral bias. Survey is retro-
spective, but given the challenging conditions we were
in, it was the only possible way of collecting data. Also, it
is based on patient records from a single hospital. Yet,
our hospital is the only centre in our region with the full
diagnostic capability for diagnosing TC, and it is ex-
plained that due to our peculiar conditions every TC pa-
tient eventually ends up in our centre. Nevertheless, we
allow for possibility that small number of patients re-
mains undetected.
Another important fact we have to mention is lack of
completely reliable data on general population in our re-
gion. Due to known reasons (war, political situation) na-
tional census has not been conducted since 1991. War ca-
sualties and extensive population migration, together
with change of administrative borders make estimation
of population numbers a very difficult task. Estimate fig-
ures we used in our paper are the best that could be obtai-
ned at the moment and are based on the official estimate
by our Federal Office of Statistics. As a consequence this
period is not optimal to conduct epidemiology studies
even if done prospectively, but it was our intention to
purposely study it, due to specific conditions. Figures
from the last 5 years of study are however, more reliable.
Despite limitations, we believe that this study brings
information of great local and regional importance. Gi-
ven the fact that data on TC epidemiology from Bosnia
and Herzegovina does not exist, providing as accurate es-
timate as possible in our setting is certainly better than
having no data at all. Also, demonstration of a possible
link between the availability of diagnostics and TC inci-
dence, in our opinion, provides a good explanation why
we are encountering increase in frequency of TC in East-
ern Europe including Bosnia.
In conclusion we demonstrated the slight decline of
incidence in our region during the observed period, but
with the increase in the latest years of the study. This in-
crease is probably the result of combination of various
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factors, mainly the better detection of new cases due to
wider availability of diagnostics. Based on depicted trends,
we believe that in the future years, TC incidence in our
region will continue to rise and it is up to prospective sur-
veys in the years to follow to confirm our projections.
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KARCINOM [TITINJA^E NA PODRU^JU TUZLANSKOG KANTONA BOSNE I HERCEGOVINE:
10 GODI[NJA STUDIJA (1999–2008)
S A @ E T A K
Bosna i Hercegovina (BiH) je jedna od dr`ava isto~ne Europe bez valjanih podataka o epidemiologiji karcinoma
{titnja~e. Ciljevi su istra`ivanja utvrditi incidenciju karcinoma {titnja~e u Tuzlanskom kantonu BiH tijekom 10-godi-
{njeg razdoblja (1999–2008).Retrospektivno smo evaluirali 65.000 medicinskih kartona, kako bolni~kih tako i ambu-
lantnih bolesnika s mogu}im simptomima bolesti {titne `lijezde, a koji su nastanjeni i Tuzlanskom kantonu (ukupno
496.280 stanovnika) u periodu izme|u 1999 i 2008. Pacijenti s histolo{ki dokazanim karcinomom {titinja~e bili su
uklju~eni u studiju. Stope incidencije izra~unate su uz dobnu standardizaciju koriste}i europsku standardnu popu-
laciju. Trendovi u incidenciji su procijenjeni koriste}i pokretni trogodi{nji prosjek. Za vrijeme posmatranog perioda 117
pacijenata je zadovoljavalo dijagnosti~ke kriterije za karcinom {titnja~e, uz omjer mu{kog i `enskog spola od 1:4.85.
Medijan dobi za sve slu~ajeve bio je 51 godina (interkvartilni raspon: 41 – 60) sa mu{karcima u prosjeku za devet godina
starijim od `ena u vrijeme uspostavljanja dijagnoze. Prosje~na standardizirana godi{nja incidencija je iznosila 2.30/105
(%95 CI = 1,38–3,22 95) stanovnika sa rasponom kretanja za vrijeme posmtranog perioda od 1,0–3,2/105 stanovnika.
Prosje~na godi{nja incidencija u mu{karaca je iznosila 0.82/105 dok je u `ena ona iznosila 3.83/105. Prevalenca karci-
noma {titinja~e na kraju promatranog perioda je iznosila 23.58/105 (% CI = 95 19,3–27,58).Postoji blagi pad incidencije
u na{oj regiji u toku posmatranog perioda, ali s pove}anjem u posljednjim godinama studije. Taj porast je vjerojatno
rezultat kombinacije razli~itih ~imbenika, uglavnom bolje detekcije novih slu~ajeva zbog {ire dostupnosti dijagnostike.
Na temelju opisanih trendova, vjerujemo da }e u narednim godinama incidencija karcinoma {titinja~e u na{oj regiji i
dalje rasti.
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